Monomeric chemically modified allergens: Immunologic and physicochemical characterization

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 51, Issue 1, 1996, Pages 8-15

  Mistrello, G ^a   Brenna, O ^b   Roncarolo, D ^a   Zanoni, D ^a   Gentili, M ^a   Falagiani, P ^a  

^a Lofarma SpA   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

Author keywords

Allergens; Monomeric modified allergens; Potassium cyanate; RAST inhibition

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E; OVALBUMIN; POTASSIUM CYANATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL MODIFICATION; IMMUNOBLOTTING; NONHUMAN; PRIORITY JOURNAL; RABBIT; RADIOALLERGOSORBENT TEST; RAT;

EID: 0029866066     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.1996.tb00003.x     Document Type: Article

References (33)

1. Anderson MC, Baer H. RAST-inhibition procedure. Allergenic Products Branch, Bureau of Biologies, Bethesda, MD: Food and Drug Administration, 1981.
2. Andri L, Senna GE, Betteli C, et al. Local nasal immunotherapy in allergic rhinitis to Parietaria. Allergy 1992;47:318-23.
3. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
4. Chen CC, Grossberg AL, Pressman D. Effect of cyanate on several anti-hapten antibodies: evidence for the presence of amino group in the site of anti-p-azobenzencarbonate antibody. Biochemistry 1962;1:1025-30.
5. De Monchy JGR, Aalberse RC, van de Zwuan JC, De Vries K. Specific IgE, IgG and IgG4 antibodies during vespid venom hyposensitization. Allergol Immunopathol 1980;8:281-6.
6. Djurup R, OØsterballe O. IgG subclass antibody response in grass pollen-allergic patients undergoing specific immunotherapy. Allergy 1984;39:433-41.
7. Durham SR. Basic mechanisms of immunotherapy [Abstract]. Annual Meeting European Academy Allergology and Clinical Immunology, Rotterdam, 12-15 September 1993. Allergy 1993;48(Suppl. 16):15.
8. Falagiani P, Brenna O, Mistrello G. Chemically modified allergens and process for the preparation thereof. 1990; European Patent no. A90830412.4.
9. Fields R. The rapid determination of amino-groups with TNBS. Methods Enzymol 1972;2513:464-8.
10. Graft DF, Schubert KC, Kagey-Sobotka A, et al. Assessment of prolonged venom immunotherapy in children. J Allergy Clin Immunol 1987;80:162-6.
11. Grammer LC, Shaughnessy MA, Patterson R. Modified forms of allergen immunotherapy. J Allergy Clin Immunol 1985;76:397-401.
12. Hopp TP. Protein surface analysis. Methods for identifying antigenic determinants and other interaction sites. J Immunol Methods 1986;88:1.
13. Hopp TP, Woods KR. Prediction of protein antigenic determinants from amino acid sequences. Proc Natl Acad Sci USA 1981;78:3834.
14. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
15. Lessof MH, Sobotka AK, Lichtenstein LM. Protection against anaphylaxis in Hymenoptera sensitive patients by passive immunization. J Allergy Clin Immunol 1976; 2:46-7.
16. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing. J Allergy Clin Immunol 1987;79:660-77.
17. Maasch HJ, Marsh DG. Standardized extracts. Modified allergens-allergoids. Clin Rev Allergy 1987;5:89-106.
18. Malling H-J, Djurup R. Diagnosis and immunotherapy of mould allergy. Allergy 1988;43:60-70.
19. Marsh DG. Properties of modified allergenic extracts. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1985;79:313-21.
20. Matoba T, Dot E, Yonezawa D. Digestibility of acetylated and succinylated proteins by pepsin-pancreatin and some intracellular peptidases. Agric Biol Chem 1980;44:2323-8.
21. Mistrello G, Rapisarda G, Falagiani P. Detection of IgE-binding activity in serum after intranasal treatment of normal rabbits with P. judaica extract. Allergy 1991; 46:52-8.
22. Mistrello G, Roncarolo D, Gentili M, Zanoni D, Falagiani P. Modified Par j I allergen from P. judaica pollen and its rate of absorption in rats. Immunol Lett 1994;40:31-6.
23. Norman PS. A review of immunotherapy. Allergy 1978;33:62-70.
24. Ovary Z. Cutaneous anaphylaxis in the albino rat. Int Arch Allergy Appl Immunol 1952;3:293-9.
25. Rees JA, Merrett TG. The rapid release (and rapid degradation) of Der p I during extraction of whole mite cultures. In: Report of Second International Workshop: Dust mite allergens and asthma. UCB Institute of Allergy, 1990.
26. Report of WHO/IUIS working group. The current status of allergen immunotherapy (hyposensitisation). Allergy 1989;44:369-79.
27. Sabbah A, Hassoun S, Le Sellin J, André C, Sicard H. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994;49:309-13.
28. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993;178:2123-30.
29. Sledge RF. Treatment of hay fever with alum precipitated pollen extract. U S Nav Med Bull 1938;36:18-20.
30. Smyth DG. Carbamylation of amino and tyrosine hydroxyl-groups. J Biol Chem 1967;242:1579-91.
31. Stark GR. Modification of proteins with cyanate. Methods Enzymol 1967;11:590-5.
32. Tamir R, Castracane JM, Rocklin RE. Generation of suppressor cells in atopic patients during immunotherapy that modulate IgE synthesis. J Allergy Clin Immunol 1987;79:591-8.
33. Yman L, Ponterius G, Brandt R. RAST-based allergen assay methods. Dev Biol Stand 1975;29:151-65.